Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 517


Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.

Prabhu VV, Allen JE, Dicker DT, El-Deiry WS.

Cancer Res. 2015 Apr 1;75(7):1423-32. doi: 10.1158/0008-5472.CAN-13-3451. Epub 2015 Feb 20.


Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS.

Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.


Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS.

Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.


Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.

Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS.

PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.


Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.

Cheng L, Liu YY, Lu PH, Peng Y, Yuan Q, Gu XS, Jin Y, Chen MB, Bai XM.

Oncotarget. 2017 Apr 25;8(17):28385-28394. doi: 10.18632/oncotarget.16073.


The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent.

Zhang Q, Wang H, Ran L, Zhang Z, Jiang R.

Biochem Biophys Res Commun. 2016 Aug 5;476(4):260-266. doi: 10.1016/j.bbrc.2016.05.106. Epub 2016 May 24.


ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.

Talekar MK, Allen JE, Dicker DT, El-Deiry WS.

Cell Cycle. 2015 Aug 3;14(15):2422-8. doi: 10.1080/15384101.2015.1054086. Epub 2015 Jun 1.


TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.

Karpel-Massler G, Bâ M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2015 Nov 3;6(34):36456-71. doi: 10.18632/oncotarget.5505.


Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.

Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS.

Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.


Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.

Wang J, Wang H, Wang LY, Cai D, Duan Z, Zhang Y, Chen P, Zou JX, Xu J, Chen X, Kung HJ, Chen HW.

Cell Death Differ. 2016 Nov 1;23(11):1886-1896. doi: 10.1038/cdd.2016.92. Epub 2016 Sep 9.


Activation of FOXO3a reverses 5-Fluorouracil resistance in human breast cancer cells.

Song Y, Lu M, Qiu H, Yin J, Luo K, Zhang Z, Jia X, Zheng G, Liu H, He Z.

Exp Mol Pathol. 2018 Aug;105(1):57-62. doi: 10.1016/j.yexmp.2018.05.013. Epub 2018 May 29.


Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.

Feng Y, Zhou J, Li Z, Jiang Y, Zhou Y.

PLoS One. 2016 Sep 14;11(9):e0162133. doi: 10.1371/journal.pone.0162133. eCollection 2016.


ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.

Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS.

Sci Signal. 2016 Feb 16;9(415):ra18. doi: 10.1126/scisignal.aac4374.


Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS.

Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10.


FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.

Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim HK, Bae KB, Park YH, Kim SU, Kim JM, Kim N, Ko KS, Rhee BD, Han J.

Gastroenterology. 2015 Oct;149(4):1006-16.e9. doi: 10.1053/j.gastro.2015.06.007. Epub 2015 Jun 17.


Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.

Shoeb M, Ramana KV, Srivastava SK.

Free Radic Biol Med. 2013 Oct;63:280-90. doi: 10.1016/j.freeradbiomed.2013.05.039. Epub 2013 May 31.


mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.

Jin ZZ, Wang W, Fang DL, Jin YJ.

Biochem Biophys Res Commun. 2016 Sep 30;478(4):1515-20. doi: 10.1016/j.bbrc.2016.08.126. Epub 2016 Aug 24.


ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.

Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS.

Mol Cancer Ther. 2017 Jul;16(7):1290-1298. doi: 10.1158/1535-7163.MCT-17-0121. Epub 2017 Apr 19.


Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.

French R, Hayward O, Jones S, Yang W, Clarkson R.

Mol Cancer. 2015 Dec 15;14:209. doi: 10.1186/s12943-015-0478-y.

Supplemental Content

Support Center